Novartis Gene Therapies - Company Profile
Powered by 
All the data and insights you need on Novartis Gene Therapies in one report.
$295
- Save hours of research time and resources with
our up-to-date Novartis Gene Therapies Strategy Report
- Understand Novartis Gene Therapies position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Novartis Gene Therapies, formerly AveXis Inc, is a biotechnology company. It operates as a subsidiary of Novartis AG. The company develops treatments for rare and potentially fatal neurological genetic diseases. The company’s product, Zolgensm is a proprietary gene therapy candidate for pediatric patients for the treatment of spinal muscular atrophy. It is also pursuing gene therapies for Rett syndrome (AVXS-201), and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301). It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. Novartis Gene Therapies is headquartered in Bannockburn, Illinois, the US.
Headquarters
United States of America
Address
Suite 200, 2275 Half Day Road, Bannockburn, Illinois, 60015
Website
www.avexis.com
Telephone
1 847 5728280
Industry
Pharmaceuticals and Healthcare
Novartis Gene Therapies premium industry data and analytics
Products and Services
| Products |
|---|
| Zolgensma |
| Pipeline: |
| AVXS-101 - Spinal Muscular Atrophy |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Novartis Gene Therapies | Biogen Inc | Ionis Pharmaceuticals Inc | Voyager Therapeutics Inc | Paratek Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bannockburn | Cambridge | Carlsbad | Lexington | Boston |
| State/Province | Illinois | Massachusetts | California | Massachusetts | Massachusetts |
| No. of Employees | - | 7,570 | 927 | 162 | 268 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dave Lennon | President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer